FindTrial
Sign In

Does cyclosporine A reduce the insulin secretion from the pancreas?

Does cyclosporine A reduce the insulin secretion from the pancreas?

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004488-31-NO
Enrollment
16
Registered
2005-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney failure / dialysis patients / transplantation

Interventions

Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral Pharmaceutical Form: Capsule, hard CAS Number: 59865-13-3 Current Sponsor code: NOVARTIS Other descriptive name: Sandimmun Neoral Concentrat

Sponsors

Rikshospitalet University Hospital, University of Oslo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Dialysis patients planned to be kidney transplanted and not treated with steroids Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Age above 75 years or below 18 years Pregnancy Lactating mothers Diabetes mellitus Less than 2 months of dilayses Coronary heart disease Ongoing corticosteroid treatment

Design outcomes

Primary

MeasureTime frame
Main Objective: Test the effect of cyclosporine A on insulin release;Secondary Objective: Test the effect of cyclosporine A on insulin action, endothelial function. Test the useage of pretransplant cyclosporine A pharmacokinetics detrminations for dose individualisation at the time of transplantation;Primary end point(s): Change in insulin secretion—

Countries

Norway

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026